comprehensive -WSS

comprehensive

author：explore 2025-09-30 14:59:02 - browse：432

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Bird flu in dairy cattle: New measures to control spread to humans

WSS

A single Democrat is willing to weaken Medicare negotiation power

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Adopting new red light myopia treatments may be short

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Texas Medical Board asked to define abortion emergency exception

knowledge

comprehensive

leisure time

At least 13 dead in Texas as scorching temps continue

Four alarming medical procedures we’re glad history forgot

Tori Bowie and the unacceptable rates of Black maternal death

Bernie brings in new pharma CEOs to talk drug prices

Walensky prepares to leave CDC — and Congress — behind

Trial using CRISPR to edit HIV out of cells disappoints

Heart attack and stroke risk calculators need revising

Researchers test human milk's ability to repair gut microbiome

Medicare proposal to cover medical devices draws a mixed reaction

Scientific mystery highlights the blind spots in genomics databases

hotspot

Scientists uncover potential path to treating deadly childhood tumor

Updated Covid vaccine has 54% effectiveness, new study suggests

Young boy dies in trial for Pfizer Duchenne gene therapy

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Multiple sclerosis has subtypes with different best treatments: study

AI gets buy

hotspot

hotspot

focus

hotspot